## EUROIMMUN

Medizinische Labordiagnostika AG

## APOE genotyping with the EURORealTime APOE

For assessment of the risk of medication side effects in anti-amyloid beta antibody therapy for Alzheimer's disease

**New active substances** for anti-amyloid beta antibody therapy of early-stage Alzheimer's disease (e.g. lecanemab, donanemab)

**Increased risk** of potentially life-threatening side effects in the form of brain swelling/bleeds (**ARIA**, amyloid-related imaging abnormalities) in carriers of two copies of the APOE allele  $\varepsilon 4$ 



**ε4/ε4 genotype** is an exclusion criterion for therapy in some countries.




**APOE genotyping** supports the proactive evaluation of the individual ARIA risk.

Find more information on genotyping by means of PCR (polymerase chain reaction) assay on the following page.

## EUROIMMUN

Medizinische Labordiagnostika AG



Regulatory status of the products must be verified for the user's individual jurisdiction. Please contact your country representative for product availability and information.

**TOGETHER AT THE PULSE OF NEUROLOGY** 



neurodiagnostics@euroimmun.de